Global Axial Spondyloarthritis (axSpA) Market Share

Statistics for the 2023 & 2024 Global Axial Spondyloarthritis (axSpA) market share, created by Mordor Intelligence™ Industry Reports. Global Axial Spondyloarthritis (axSpA) share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Axial Spondyloarthritis (axSpA) Industry

The axial spondyloarthritis market is fragmented, competitive, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Johnson & Johnson, UCB, Amgen, Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Kyowa Kirin, AbbVie, Acelyrin, and Pfizer.

Axial Spondyloarthritis (axSpA) Market Leaders

  1. Janssen Biotech

  2. AbbVie

  3. UCB

  4. Amgen

  5. Novartis Pharmaceuticals Corporation

*Disclaimer: Major Players sorted in no particular order

Janssen Biotech, AbbVie, UCB, Amgen, Novartis Pharmaceuticals Corporation

Axial Spondyloarthritis (axSpA) Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)